menu
    • menu

    Company profile for Alveus Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alveus Therapeutics, a clinical-stage biotech firm, develops next-generation therapies targeting obesity and metabolic diseases. These innovative treatments prioritize sustained efficacy, enhanced tolerability, and lower treatment burden to address critical unmet needs. Leveraging advanced science, Alveus aims to transform patient outcomes in cardiometabolic health.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alveus TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Two Logan Square Suite 1930 Philadelphia, PA 19103
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alveustx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alveus-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Slate, Alveus Raise Hefty Series Hauls for Migraine, Obesity Drug
    Slate, Alveus Raise Hefty Series Hauls for Migraine, Obesity Drug

    25 Feb 2026

    // BIOSPACE

    https://www.biospace.com/business/slate-alveus-raise-hefty-series-a-hauls-for-migraine-obesity-drugs

    BIOSPACE
    25 Feb 2026
    Share Share
    Alveus Raises $197M in Series A for Obesity Drugs
    Alveus Raises $197M in Series A for Obesity Drugs

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243418/0/en/Alveus-Therapeutics-Announces-Second-and-Final-Closing-of-Oversubscribed-Series-A-Bringing-Total-Financing-to-197-Million-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metab.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Alveus Therapeutics Initiates Phase 1B Trial For ALV-100
    Alveus Therapeutics Initiates Phase 1B Trial For ALV-100

    23 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/23/3224643/0/en/Alveus-Therapeutics-Announces-FDA-Clearance-of-IND-and-First-Patient-Dosed-in-Phase-1b-Trial-of-ALV-100-for-Obesity.html

    GLOBENEWSWIRE
    23 Jan 2026
    Share Share
    InterAx, Alveus Sign Research & Licensing Deal for Metabolic Drug
    InterAx, Alveus Sign Research & Licensing Deal for Metabolic Drug

    15 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260115622477/en/InterAx-and-Alveus-Announce-Strategic-Research-and-Licensing-Agreement-to-Develop-Differentiated-Therapeutic-Candidate-for-Metabolic-Disease

    BUSINESSWIRE
    15 Jan 2026
    Share Share
    Alveus Therapeutics Raises $160M Series A for Obesity Drugs
    Alveus Therapeutics Raises $160M Series A for Obesity Drugs

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215272/0/en/Alveus-Therapeutics-Launches-with-160-Million-Series-A-Financing-to-Advance-Next-Generation-Therapies-for-Obesity-and-Metabolic-Diseases.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search